Why measure levels of immunity to COVID-19?
By estimating immunity or measuring the real-world effectiveness of vaccination programs, we can better manage public health risks and guide the reopening of our societies.
Individual Booster Requirements
Measuring neutralising antibody levels with cPass™ may determine how long immunity lasts and can help inform decision making about booster requirements.
Immuno-compromised
and elderly
In immuno-compromised individuals, an effective vaccination strategy together with cPass™ may offer an added level of assurance to those most vulnerable.
Risk Stratification
An understanding of infection and illness risk empowers effective decision making. cPass™ may help inform public health policy, business management and personal peace of mind.
IBH has distribution rights to commercialise, launch and supply cPass™ and cPass Express™ in Australia, New Zealand, South Pacific Islands, Bangladesh, Philippines and Indonesia
International Travel
Concerns related to cross border spread of COVID-19 can possibly be minimised using cPass™. Travel decisions may be more confidently informed when venturing into areas with increased health and safety risks.
Neutralising antibodies:
an important biomarker
of immunity.
cPass™, the first FDA-authorised test for neutralising antibodies (NAb) against the SARS-CoV-2 virus.
cPass™ directly measures NAb, a type of antibody produced by the immune system against SARS-CoV-2.
NAb directly block the SARS-CoV-2 virus from entering human cells, making them the most important biomarker of immunity.
Contact us to learn more about cPass™.